Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials

Overview of attention for article published in Frontiers in endocrinology, December 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 15 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 6,870 followers.

RT @FrontEndocrinol: New Research: Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure:…

21 Dec 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure:…

21 Dec 2023

Reply Repost Favourite

Individual differences among SGLT2Is in T2D and HF 🆕 ⬇️ Hospitalization for 🫀 failure: canagliflozin > sotagliflozin > empagliflozin (top 3) ⬇️ CV death: No difference between SGLT2Is All cause mortality: Only dapagliflozin

20 Dec 2023

Reply Repost Favourite

RT @FrontEndocrinol: New Research: Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure:…

20 Dec 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.